Get the Stockscreener App
8.56
5.03%
0.41
After Hours:
8.73
0.17
+1.99%
Immix Biopharma Inc stock is traded at $8.56, with a volume of 560.84K.
It is up +5.03% in the last 24 hours and up +39.87% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$8.15
Open:
$8.23
24h Volume:
560.84K
Relative Volume:
0.54
Market Cap:
$453.30M
Revenue:
-
Net Income/Loss:
$-23.56M
P/E Ratio:
-10.89
EPS:
-0.7861
Net Cash Flow:
$-15.45M
1W Performance:
-2.17%
1M Performance:
+39.87%
6M Performance:
+290.87%
1Y Performance:
+425.15%
1-Day Range:
$8.23
$8.8999
1-Week Range:
$7.82
$8.8999
52-Week Range:
$1.34
$8.97
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.56 | 431.58M | 0 | -23.56M | -15.45M | -0.7861 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Immix Biopharma to Participate in Upcoming Investor Conferences - GlobeNewswire
Insider Buy: What dividend growth rate does Immix Biopharma Inc offerTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
IMMX Should I Buy - Intellectia AI
IMMX Technical Analysis & Stock Price Forecast - Intellectia AI
IMMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investment manager Saturn V holds 6.97% of Immix Biopharma (IMMX) - Stock Titan
Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long - simplywall.st
Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Rises By 31.9% - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX) - Yahoo Finance
Immix Biopharma (NASDAQ:IMMX) Now Covered by Mizuho - MarketBeat
Mizuho Initiates Immix Biopharma at Outperform With $14 Price Target - marketscreener.com
Mizuho initiates coverage of Immix Biopharma (IMMX) with outperform recommendation - MSN
Immix Biopharma (NASDAQ:IMMX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Stock Recap: Whats the MACD signal for Immix Biopharma IncJuly 2025 Selloffs & Safe Entry Point Alerts - baoquankhu1.vn
Is Immix Biopharma Inc. stock a good pick for beginnersJuly 2025 Volume & High Accuracy Investment Entry Signals - mfd.ru
FDA grants breakthrough therapy status to ImmixBio’s amyloidosis drug By Investing.com - Investing.com Canada
Immix Biopharma stock climbs after FDA grants breakthrough therapy status By Investing.com - Investing.com Canada
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 - GlobeNewswire
FDA grants Breakthrough status to NXC-201 in AL amyloidosis with no approved drugs - Stock Titan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Market Recap: Why Immix Biopharma Inc. stock remains undervaluedQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Is Immix Biopharma Inc stock a good pick for beginnersMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Published on: 2026-01-13 06:33:30 - Улправда
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Benzinga
Immix Biopharma (NASDAQ:IMMX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Immix Biopharma to offer and sell up to $750 million in securitiesSEC filing - marketscreener.com
Immix Biopharma — NXC-201’s path to BLA submission - Smartkarma
Why analysts upgrade Immix Biopharma Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - ulpravda.ru
Why Immix Biopharma Inc. stock is a must watch in 2025July 2025 Decliners & High Accuracy Investment Entry Signals - Улправда
Why Immix Biopharma Inc. stock remains undervalued2025 Earnings Impact & High Return Trade Guides - Улправда
What technical charts say about Immix Biopharma Inc. stock2025 Support & Resistance & Weekly Watchlist for Hot Stocks - ulpravda.ru
What momentum indicators show for Immix Biopharma Inc. stockRate Hike & Accurate Intraday Trading Signals - ulpravda.ru
Fed Watch: Why analysts upgrade Immix Biopharma Inc stockWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - Bộ Nội Vụ
Swing Trade: Can Immix Biopharma Inc stock surprise with earnings upsidePortfolio Update Report & Consistent Profit Alerts - moha.gov.vn
Why Immix Biopharma Inc stock remains undervaluedJuly 2025 Patterns & Fast Exit and Entry Trade Guides - moha.gov.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December - MarketBeat
Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World
Immix Biopharma (IMMX) price target increased by 50.00% to 12.24 - MSN
Immix Biopharma (IMMX) Price Target Increased by 50.00% to 12.24 - Nasdaq
Is Immix Biopharma Inc. stock resilient to inflation2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда
Is Immix Biopharma Inc. stock positioned well for digital economyTake Profit & Expert Curated Trade Setups - Улправда
Why Immix Biopharma Inc. stock remains on buy listsPortfolio Return Report & Precise Swing Trade Entry Alerts - DonanımHaber
Is Immix Biopharma Inc. stock positioned for long term growth2025 Retail Activity & Free Risk Controlled Daily Trade Plans - DonanımHaber
What hedge fund activity signals for Immix Biopharma Inc. stock2025 Sector Review & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World
Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in
Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn
FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):